Hatteras Venture Partners — 2023 Investments
2 investments dated 2023 · listed companies and verified rows first · show all
ilumivu builds software platforms for behavioral and clinical research, including tools for running clinical trials, patient engagement, and multisite collaborative research using wearable and mobile technology.
AI & Machine LearningDigital HealthHealthtechMental HealthSaaSFairview, US
Mark Tuomenoksa(Co-Founder & Chief Technology Officer)inLauren Pierce Flickinger(Chief Executive Officer)inKate Rahimzadeh(Chief Operating Officer)Sandeep Goel(Executive Officer, Director, Promoter)
Board seatLauren Pierce Flickinger· per SEC Form D
Tune Therapeutics develops a therapeutic platform targeting the epigenome to treat complex diseases and regenerative medicine applications.
BiotechDeep TechHealthtechLongevityMedical DevicesDurham and Seattle, US
Akira Matsuno(Executive Officer)Derek Jantz(Executive Officer)inCharles Gersbach(Director)inJohn McHutchison(CEO, Chairman of the Board)Dan McHugh(Executive Officer, Director)Blythe Sather(Executive Officer)
Co-investorsDuke Capital PartnersMission BiocapitalNew Enterprise Associates (NEA)Yosemite
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.